Table 4.
Combinatorial CPI clinical trials in STS.
| Year/Author | Trial | Agents | Evaluable Patients (n) | ORR | Other Outcomes |
|---|---|---|---|---|---|
| 2019 Wilky [85] |
Miami single-centre phase II | Pembrolizumab and axitinib | 30 | 27% (55% ASPS ORR) | 8 PR (6 ASPS, 1 ES, 1 LMS) 9 SD 3 minor responses (1 LMS, 1 SS, 1 UPS) 4.7-month mPFS |
| 2020 Martin-Broto [86] |
IMMUNOSARC multicentre phase Ib/II | Nivolumab and sunitinib | 58 (12 phase Ib, 46 phase II) | 21% (57% ASPS ORR) | Phase II: 1 CR 5 PR 33 SD 7 PD |
| 2017 Toulmonde [93] |
PEMBROSARC phase II | Pembrolizumab + metronomic cyclophosphamide | 50 | 2% | 1 PR 16 SD 31 PD 2 minor responses |
| 2021 Italiano [47] |
Tertiary lymphoid structure selected PEMBROSARC phase II | Pembrolizumab + metronomic cyclophosphamide | 30 | 27% | 5 SD 4.1-month mPFS |
| 2017 Weiss [95] |
PembroPlus phase 1b | Pembrolizumab and doxorubicin/gemcitabine/docetaxel | 6 | 0% | 1 SD 5 PD |
| 2020 Pollack [96] |
Phase I/II | Pembrolizumab and doxorubicin | 37 | 19% | 7 PR 2 unconfirmed PR 11 SD 8.1-month mPFS |
Abbreviations: ASPS, alveolar soft part sarcoma; CR, complete response; ES, epithelioid sarcoma; LMS, leiomyosarcoma; mPFS, median progression-free survival; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; SS, synovial sarcoma; UPS, undifferentiated pleomorphic sarcoma.